Timothy Cloughesy6
Phioanh L Nghiemphu6
6Timothy Cloughesy
6Phioanh L Nghiemphu
Learn More
<i>Most software systems are inflexible. Reconfiguring a system's modules to add or to delete a feature requires substantial effort. This inflexibility increases the costs of building variants of a system, amongst other problems.</i> <i>New languages and tools that are being developed to provide additional support for separating concerns show promise to(More)
W Wouldn't it be advantageous to know in advance that the use of AOP [3] for your next project would be successful? Unfortunately, developers and managers seldom have access to evidence assuring them that the benefits promised by a new technology, such as AOP, will be achieved if they adopt the technology. Instead, they must take a leap of faith, believing(More)
BACKGROUND Glioblastomas are the most common primary brain tumour in adults. While the prognosis for patients is poor, gene expression profiling has detected signatures that can sub-classify GBMs relative to histopathology and clinical variables. One category of GBM defined by a gene expression signature is termed ProNeural (PN), and has substantially(More)
Accurate clinical assessment of a patient's response to treatment for glioblastoma multiforme (GBM), the most malignant type of primary brain tumor, is undermined by the wide patient-to-patient variability in GBM dynamics and responsiveness to therapy. Using computational models that account for the unique geometry and kinetics of individual patients'(More)
  • Irmgard Hofmann, Andreas Weiss, Gaelle Elain, Maria Schwaederle, Dario Sterker, Vincent Romanet +8 others
  • 2012
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much effort has been focused on developing drugs targeting components of these pathways. To better understand the(More)
BACKGROUND There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patients who are more likely to benefit. Small, molecularly focused clinical studies offer the promise of(More)
Oculodentodigital dysplasia (ODDD) is a rare developmental disorder characterized by craniofacial and limb abnormalities. Over 35 separate mutations in human connexin43 (Cx43) causing ODDD have been identified. Several mutations are also associated with central nervous system involvement, including white-matter changes detected by magnetic resonance(More)
Current therapies for glioblastoma (GBM) target bulk tumor through measures such as resection and radiotherapy. However, recent evidence suggests that targeting a subset of tumor cells, so-called cancer stem cells, may be critical for inhibiting tumor growth and relapse. The subventricular zone (SVZ), which lines the ventricles of the brain, is thought to(More)
Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) are distinct from other subtypes in their relatively restricted localization to the striatum and some other brain regions. The effect of nicotine treatment on nAChR subtypes has been extensively investigated, with the exception of changes in alpha-conotoxin MII-sensitive receptor(More)